Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels greater than or equal to 500 mg/dL and less than or equal to 2000 mg/dL.

Trial Profile

Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels greater than or equal to 500 mg/dL and less than or equal to 2000 mg/dL.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms MARINE
  • Sponsors Amarin Corporation
  • Most Recent Events

    • 28 Nov 2018 According to a Cardax Pharmaceuticals media release, Paresh N. Soni, M.D., Ph.D led the development of this clinical trial and regulatory strategy.
    • 31 Aug 2018 Biomarkers information updated
    • 01 Nov 2016 Results (n=215) of subgroup analyses of MARINE and ANCHOR trials published in the American Journal of Cardiology (2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top